Add BrightSurf on Google Email

Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy

The company's ATA-200 gene therapy has shown safety, pharmacodynamics, and efficacy results in the first patients treated, offering hope for children with LGMD-R5. The therapy delivers a normal copy of the γ-sarcoglycan gene and has been awarded Orphan Drug Designation in the US and Europe.

From cytoplasm to nucleus: A new workflow to improve gene therapy odds

Researchers at the University of California - San Diego have developed a new method to improve gene therapy by increasing the efficacy of gene delivery while minimizing harmful side effects. The new workflow allows for increased control of nuclear DNA delivery, with greater than tenfold increase in nuclear DNA delivery observed.

SourceUniversity of California - San Diego·JournalNature Communications·TypeExperimental study·DateFeb 4, 2026

RNA therapy may be a solution for infant hydrocephalus

A new study by McGill University researchers offers a potential solution for infant hydrocephalus, a life-threatening condition that affects 1 in 1,000 newborns. RNA therapy has been shown to prevent the condition in mice models, with a promising impact on treating genetically caused hydrocephalus.

SourceMcGill University·JournalMolecular Therapy·TypeExperimental study·DateJan 30, 2026

Breakthrough on gene therapy for hereditary spastic paraplegia

Researchers at Drexel University and UMass Chan Medical School have developed a gene therapy approach that silences and replaces disease-causing genes in mice with hereditary spastic paraplegia. The treatment prevents nerve breakdown and symptoms, offering a potential cure for the rare disease. Studies suggest that the therapy could be...

SourceDrexel University·JournalMolecular Therapy·TypeExperimental study·DateDec 15, 2025

Nonsurgical treatment shows promise for targeted seizure control

A nonsurgical approach has been demonstrated to quiet a specific brain circuit in an animal model by delivering engineered gene therapy only to the targeted region. The method uses low-intensity focused ultrasound to open the blood-brain barrier, allowing precise control over brain activity without impacting off-target areas.

SourceRice University·JournalACS Chemical Neuroscience·TypeExperimental study·DateNov 11, 2025

A specific human gene can help the heart repair itself from heart attack or heart failure

A naturally occurring gene called Cyclin A2, normally silenced in humans, can make new functioning heart cells and aid in the heart's repair. The breakthrough discovery could lead to new techniques for repairing damaged hearts as an alternative to transplants or implanted cardiac devices.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·Journalnpj Regenerative Medicine·TypeExperimental study·DateNov 3, 2025

Researchers unveil a powerful new gene-switch tool

Researchers at Weill Cornell Medicine have developed a powerful new gene-switch tool called Cyclone, which allows scientists to turn on or off target genes with precision. The tool uses a non-toxic molecule acyclovir to suppress gene activity, and has the potential to be adopted throughout biomedical research and gene therapies.

SourceWeill Cornell Medicine·JournalNature Methods·DateNov 3, 2025

Landmark gene therapy study shows safety for children

A landmark study published in the New England Journal of Medicine reports the long-term safety and efficacy of gene therapy for children with ADA-SCID, a rare immune disorder. The treatment resulted in a 100% survival rate and over 95% cure rate, with patients able to respond to routine childhood vaccinations.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeObservational study·DateOct 15, 2025

MIT researchers develop a new system can dial expression of synthetic genes up or down

Researchers at MIT have developed a new system that allows for precise control over the expression of synthetic genes in cells. The DIAL system uses a promoter editing mechanism to establish desired protein levels, which can be edited after delivery. This technology has the potential to improve gene therapy and cell reprogramming appli...

SourceMassachusetts Institute of Technology·JournalNature Biotechnology·DateOct 14, 2025

Scientists fix genetic defect in mice tied to brain disorders that include autism and epilepsy

Researchers developed a new gene therapy that reversed symptoms related to SYNGAP1-related disorders in mice, including intellectual disability, epilepsy, and risk-taking behaviors. The therapy successfully delivered a working copy of the SYNGAP1 gene into brain cells using an adeno-associated virus, offering hope for treatment in humans.

SourceAllen Institute·JournalMolecular Therapy·TypeExperimental study·DateOct 9, 2025

Clonogenic hepatocytes drive postnatal liver growth and unlock new avenues for pediatric gene therapy

A study published in the Journal of Hepatology reveals that only 15-20% of neonatal liver cells are responsible for generating over 90% of the adult liver mass. This finding has major implications for pediatric gene therapy, allowing scientists to achieve more effective and durable correction of inherited liver diseases.

SourceFondazione Telethon·JournalJournal of Hepatology·TypeExperimental study·DateAug 28, 2025

Gene therapy leads to improved quality of life in patients with sickle cell disease and beta thalassemia

Treatment with exagamglogene autotemcel (exa-cel) leads to clinically meaningful improvements in overall quality of life for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Patients experience substantial improvements in physical, social, functional, and emotional well-being, with sustained benefits...

SourceAmerican Society of Hematology·JournalBlood Advances·DateAug 27, 2025

Promising new method could treat inherited diseases

Researchers at the University of Waterloo have developed a novel method using modified M13 bacteria to deliver targeted gene therapies for genetic disorders. This approach shows promise as a cost-effective alternative to current methods, which can be expensive and trigger toxic side effects.

SourceUniversity of Waterloo·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateAug 20, 2025

Macromolecular gene delivery systems: Advancing non-viral therapeutics with synthetic and natural polymers

Macromolecular gene delivery systems are advancing non-viral therapeutics by overcoming challenges like lower transfection efficiency and stability issues. Innovations in polymer design, functionalization, and targeting mechanisms are paving the way for clinically viable non-viral treatments.

SourceXia & He Publishing Inc.·JournalJournal of Exploratory Research in Pharmacology·DateAug 19, 2025

Research spotlight: organoids could make gene therapy trials safer by identifying hidden risks early on

Researchers used human stem cell-derived kidney organoids to test the safety of gene editing delivered by AAV, a common tool in clinical trials. The study found that AAV2 caused significant harm to kidney cells through the NFκB pathway, but an existing drug was able to prevent this damage without interfering with gene delivery.

SourceMassachusetts General Hospital·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateAug 18, 2025

‘Controlled evolution’ dramatically boosts pDNA production for biomedical manufacturing

Researchers at North Carolina State University have developed a controlled evolution technique that dramatically increases plasmid DNA (pDNA) production in E. coli bacteria. This breakthrough could significantly reduce the cost of gene therapies and expedite research, making pDNA resources more accessible.

SourceNorth Carolina State University·JournalMicrobial Cell Factories·TypeExperimental study·DateAug 13, 2025

AI meets CRISPR for precise gene editing

A research team developed a new method to precisely edit DNA by combining genetic engineering with artificial intelligence. The technique enables accurate modeling of human diseases and lays the groundwork for next-generation gene therapies.

SourceUniversity of Zurich·JournalNature Biotechnology·TypeExperimental study·DateAug 12, 2025